Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 146
interventional 136
Observational 7
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 51
Drug|Other 25
Biological|Drug 7
Biological|Drug|Procedure|Radiation 5
Biological|Other 5
Drug|Other|Procedure|Radiation 5
Drug|Procedure 5
Biological 4
Drug|Genetic|Other 4
Drug|Procedure|Radiation 4
Drug|Other|Procedure 3
Biological|Drug|Other 2
Biological|Drug|Other|Procedure|Radiation 2
Dietary Supplement|Other 2
Biological|Drug|Genetic|Other 1
Biological|Drug|Other|Procedure 1
Biological|Drug|Procedure 1
Biological|Drug|Radiation 1
Biological|Genetic|Other 1
Biological|Other|Procedure 1
Biological|Procedure|Radiation 1
Dietary Supplement|Drug 1
Drug|Genetic|Procedure|Radiation 1
Genetic 1
Other 1
Other|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 85
China 10
United States|Canada 7
United States|Italy 5
United States|Germany|Italy 3
France 2
Italy 2
United Kingdom 2
Austria 1
Belgium|Croatia|Czechia|Hungary|Poland|Portugal|Romania|Spain|Turkey|United Kingdom 1
Belgium|France|Germany|Italy|Netherlands|Norway|Poland|Slovakia|Slovenia|United Kingdom 1
Belgium|Lithuania|Spain 1
Germany 1
Korea, Republic of 1
Korea, Republic of|Malaysia|Singapore 1
NA 1
United States|Australia|Austria|Belgium|Brazil|France|Germany|Italy|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia|Belgium|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Poland|Romania|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|Puerto Rico|Switzerland 1
United States|Australia|Japan|Korea, Republic of 1
United States|Belgium|Canada|France|United Kingdom 1
United States|Canada|China|France|Germany|Hong Kong|Italy|Taiwan 1
United States|Denmark|Germany 1
United States|France 1
United States|France|Germany|Italy|Mexico|Netherlands|Spain|United Kingdom 1
United States|Germany 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 67
2 10
3 7
4 5
5 9
6 3
7 2
8 1
9 2
10 2
11 5
13 2
17 1
18 2
19 1
20 1
21 1
22 1
23 2
25 2
28 1
34 2
36 1
40 1
41 1
144 1
145 1
159 1
161 1

Phase

Phase Study_Count
Phase 2 52
Phase 1 46
Phase 1/Phase 2 22
N/A 9
Phase 3 3
Phase 4 3
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 106
2 15
3 6
4 1
6 2
7 1
9 1
NA 4

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 33 5.0000 2.00000 10.00000 5.00000 129.0000 20.0000
1st Qu. 33 62.0000 20.00000 36.25000 32.25000 130.0000 32.5000
Median 33 80.0000 34.00000 52.00000 50.50000 131.0000 45.0000
Mean 33 170.6667 48.08889 64.18182 76.03846 237.3333 238.3333
3rd Qu. 33 174.0000 52.00000 86.75000 81.75000 291.5000 347.5000
Max. 33 713.0000 596.00000 140.00000 582.00000 452.0000 650.0000

Trial Group Type

group_type Group_Count
Experimental 176
Active Comparator 7
NA 4
No Intervention 2
Other 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 109
Parallel Assignment 21
Sequential Assignment 3
NA 2
Crossover Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 131
Supportive Care 3
Basic Science 2

Observational Studies

Studies by Country

Country Study_Count
France 1
Japan 1
Korea, Republic of 1
NA 1
Russian Federation 1
United States 1
United States|Canada 1

Sites per Study

Site_count Study_Count
1 4
15 2
107 1

Enrollment Metrics

Measure Observational
Min 7.0
1st Qu 96.5
Median 205.0
Mean 586.0
3rd Qu 348.5
Max 3000.0

Observation Model

observational_model Study_Count
Cohort 4
Case-Only 2
NA 1

Time Perspective

time_perspective Study_Count
Prospective 4
Other 1
Retrospective 1
NA 1

Registries

Studies by Country

Country Study_Count
Belgium|France 1
Korea, Republic of 1
United States|Australia 1

Sites per Study

Site_count Study_Count
1 1
2 1
31 1

Enrollment Metrics

Measure Registries
Min 150.000
1st Qu 150.000
Median 150.000
Mean 6766.667
3rd Qu 10075.000
Max 20000.000

Registry Model

observational_model Study_Count
Cohort 2
Case-Only 1

Time Perspective

time_perspective Study_Count
Other 2
Prospective 1

Follow-up

target_duration Study_Count
100 Years 1
13 Years 1
3 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03947255 A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03947255 Recruiting Seattle Genetics, Inc. 2024-12-31
NCT03409432 Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03409432 Recruiting Ohio State University Comprehensive Cancer Center 2021-04-30
NCT03278782 Study of Pembrolizumab (MK-3475) in Combination With Romidepsin https://ClinicalTrials.gov/show/NCT03278782 Active, not recruiting M.D. Anderson Cancer Center 2020-11-30
NCT03113500 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03113500 Recruiting City of Hope Medical Center 2021-01-21
NCT03017820 VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03017820 Recruiting Mayo Clinic 2021-01-15
NCT02978625 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers https://ClinicalTrials.gov/show/NCT02978625 Recruiting National Cancer Institute (NCI) 2021-06-01
NCT02939014 Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) https://ClinicalTrials.gov/show/NCT02939014 Completed Takeda 2018-08-02
NCT02902874 Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + https://ClinicalTrials.gov/show/NCT02902874 Recruiting Gustave Roussy, Cancer Campus, Grand Paris 2018-10-31
NCT02652715 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02652715 Completed Mayo Clinic 2018-12-21
NCT01028716 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01028716 Recruiting Fred Hutchinson Cancer Research Center 2024-01-04
NCT02572453 Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT02572453 Active, not recruiting National Cancer Institute (NCI) 2020-10-01
NCT02561273 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02561273 Active, not recruiting University of Nebraska 2020-10-31
NCT03397953 Vinorelbine for Recurrent ACLC https://ClinicalTrials.gov/show/NCT03397953 Recruiting Children’s Cancer Group, China 2018-12-31
NCT02533700 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL https://ClinicalTrials.gov/show/NCT02533700 Active, not recruiting Shandong Provincial Hospital 2019-05-31
NCT02462538 Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL https://ClinicalTrials.gov/show/NCT02462538 Active, not recruiting Arbeitsgemeinschaft medikamentoese Tumortherapie 2021-06-30
NCT02232516 Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02232516 Recruiting Northwestern University 2022-07-31
NCT02223208 Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02223208 Recruiting Fondazione Italiana Linfomi ONLUS 2021-09-30
NCT02168140 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02168140 Active, not recruiting Wake Forest University Health Sciences 2019-04-18
NCT03383965 CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas https://ClinicalTrials.gov/show/NCT03383965 Recruiting Immune Cell, Inc. 2020-12-31
NCT01309789 A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms https://ClinicalTrials.gov/show/NCT01309789 Completed Seattle Genetics, Inc. 2013-04-30
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01950364 A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT01950364 Completed Millennium Pharmaceuticals, Inc. 2014-10-31
NCT01943682 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma https://ClinicalTrials.gov/show/NCT01943682 Completed Children’s Hospital Medical Center, Cincinnati 2019-03-31
NCT01909934 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT01909934 Recruiting Takeda 2020-09-30
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01787409 Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency https://ClinicalTrials.gov/show/NCT01787409 Recruiting Mayo Clinic 2020-11-30
NCT01777152 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas https://ClinicalTrials.gov/show/NCT01777152 Active, not recruiting Seattle Genetics, Inc. 2018-08-15
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01719835 CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study https://ClinicalTrials.gov/show/NCT01719835 Active, not recruiting Royal Marsden NHS Foundation Trust 2016-11-30
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01657331 Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) https://ClinicalTrials.gov/show/NCT01657331 Active, not recruiting Columbia University 2019-12-31
NCT01606878 Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT01606878 Completed Children’s Oncology Group 2018-12-31
NCT01590732 Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01590732 Completed M.D. Anderson Cancer Center 2018-05-02
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01578499 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) https://ClinicalTrials.gov/show/NCT01578499 Completed Takeda 2016-05-31
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01524926 CREATE: Cross-tumoral Phase 2 With Crizotinib https://ClinicalTrials.gov/show/NCT01524926 Active, not recruiting European Organisation for Research and Treatment of Cancer - EORTC 2017-12-06
NCT01492088 Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01492088 Completed Takeda 2016-10-12
NCT01466881 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01466881 Completed National Cancer Institute (NCI) 2014-12-31
NCT01449461 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) https://ClinicalTrials.gov/show/NCT01449461 Completed Takeda 2015-11-16
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01336933 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01336933 Completed University of Nebraska 2016-12-28
NCT01336920 Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01336920 Completed University of Nebraska 2015-04-30
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT04423926 Lenalidomide in Combination With CHOP in Patients With Untreated PTCL https://ClinicalTrials.gov/show/NCT04423926 Recruiting The First Affiliated Hospital with Nanjing Medical University 2022-12-31
NCT04306887 A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) https://ClinicalTrials.gov/show/NCT04306887 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2022-12-31
NCT04058470 Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma https://ClinicalTrials.gov/show/NCT04058470 Recruiting Sun Yat-sen University 2022-12-30
NCT04008394 Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies https://ClinicalTrials.gov/show/NCT04008394 Recruiting Wuhan Union Hospital, China 2022-07-01
NCT03905135 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies https://ClinicalTrials.gov/show/NCT03905135 Recruiting National Institutes of Health Clinical Center (CC) 2022-03-01
NCT03719898 Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT03719898 Recruiting Fox Chase Cancer Center 2020-12-31
NCT03707847 Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL https://ClinicalTrials.gov/show/NCT03707847 Recruiting Zhengzhou University 2020-02-01
NCT03703050 Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) https://ClinicalTrials.gov/show/NCT03703050 Recruiting Gustave Roussy, Cancer Campus, Grand Paris 2024-01-31
NCT03602157 Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL https://ClinicalTrials.gov/show/NCT03602157 Recruiting UNC Lineberger Comprehensive Cancer Center 2026-09-30
NCT03598998 Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT03598998 Recruiting City of Hope Medical Center 2021-04-27
NCT03590574 Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03590574 Recruiting Autolus Limited 2021-07-31
NCT03505554 A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma https://ClinicalTrials.gov/show/NCT03505554 Recruiting University of Milano Bicocca 2019-12-31
NCT03493451 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms https://ClinicalTrials.gov/show/NCT03493451 Active, not recruiting BeiGene 2021-02-28
NCT03443128 Vinorelbine for Recurrent ALCL-2017 https://ClinicalTrials.gov/show/NCT03443128 Recruiting Children’s Cancer Group, China 2024-12-31
NCT01261247 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01261247 Active, not recruiting Mayo Clinic 2016-05-09
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT01198665 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT01198665 Completed Samsung Medical Center 2014-12-31
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01134341 Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01134341 Completed Acrotech Biopharma LLC 2015-08-31
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01129180 Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01129180 Completed Ohio State University Comprehensive Cancer Center 2012-05-31
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT01035463 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy https://ClinicalTrials.gov/show/NCT01035463 Completed University of Nebraska 2017-07-27
NCT01026415 Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) https://ClinicalTrials.gov/show/NCT01026415 Completed Seattle Genetics, Inc. 2012-05-31
NCT01026233 Cardiac Safety Study of Brentuximab Vedotin (SGN-35) https://ClinicalTrials.gov/show/NCT01026233 Completed Seattle Genetics, Inc. 2010-08-31
NCT00994500 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma https://ClinicalTrials.gov/show/NCT00994500 Completed National Cancer Institute (NCI) 2011-07-31
NCT00947856 A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study https://ClinicalTrials.gov/show/NCT00947856 Completed Seattle Genetics, Inc. 2013-03-31
NCT00939770 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT00939770 Completed Children’s Oncology Group 2018-12-31
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00901147 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00901147 Completed Singapore General Hospital 2014-01-31
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00866047 A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT00866047 Completed Seattle Genetics, Inc. 2010-08-31
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT01686165 Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL https://ClinicalTrials.gov/show/NCT01686165 Completed University of Arizona 2016-02-09
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) https://ClinicalTrials.gov/show/NCT02568267 Recruiting Hoffmann-La Roche 2022-12-01
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00720135 Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00720135 Completed City of Hope Medical Center 2014-07-31
NCT00697346 Study of MLN8237 in Participants With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT00697346 Completed Takeda 2016-10-01
NCT00644189 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00644189 Active, not recruiting Massachusetts General Hospital 2013-12-31
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00606645 Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT00606645 Completed Xencor, Inc. 2010-04-30
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00585195 A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT00585195 Active, not recruiting Pfizer 2020-04-30
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT00430846 Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00430846 Completed Seattle Genetics, Inc. 2009-07-31
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00343798 A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00343798 Completed Fred Hutchinson Cancer Research Center 2013-07-31
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00278382 Sorafenib in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00278382 Completed National Cancer Institute (NCI) 2007-12-31
NCT00199082 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt’s Non-Hodgkin’s Lymphoma (NHL) and Other High-grade Lymphoma in Adults https://ClinicalTrials.gov/show/NCT00199082 Completed Johann Wolfgang Goethe University Hospital 2010-06-30
NCT00131937 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00131937 Completed National Cancer Institute (NCI) 2011-09-30
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00117988 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00117988 Completed National Cancer Institute (NCI) 2010-04-30
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00105001 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00105001 Completed Fred Hutchinson Cancer Research Center 2011-05-31
NCT00099255 Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT00099255 Completed Seattle Genetics, Inc. 2007-02-28
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00082888 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00082888 Completed National Cancer Institute (NCI) 2009-05-20
NCT00005080 506U78 in Treating Patients With Lymphoma https://ClinicalTrials.gov/show/NCT00005080 Completed National Cancer Institute (NCI) 2006-01-31
NCT00079755 Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT00079755 Completed Seattle Genetics, Inc. 2006-12-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00077155 Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00077155 Completed National Cancer Institute (NCI) 2010-06-30
NCT00073918 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00073918 Completed Fred Hutchinson Cancer Research Center 2011-10-02
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00059839 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT00059839 Completed Children’s Oncology Group 2009-12-31
NCT00058019 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00058019 Completed National Cancer Institute (NCI) 2010-08-31
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00016094 S0108 Bevacizumab in Treating Patients With Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00016094 Completed National Cancer Institute (NCI) 2005-08-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma https://ClinicalTrials.gov/show/NCT00004241 Completed National Cancer Institute (NCI) 2006-05-31
NCT00003970 Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00003970 Completed National Cancer Institute (NCI) 2003-10-31
NCT00003741 Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00003741 Completed National Cancer Institute (NCI) NA
NCT00001337 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00001337 Recruiting National Institutes of Health Clinical Center (CC) 2021-03-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03040206 Risk Stratification of Nodal PTCL https://ClinicalTrials.gov/show/NCT03040206 Completed Chonbuk National University Hospital 2017-06-30
NCT02139592 Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) “Relapsed or Refractory CD30+ Hodgkin’s Lymphoma or Anaplastic Large Cell Lymphoma” https://ClinicalTrials.gov/show/NCT02139592 Completed Takeda 2017-06-30
NCT01793233 Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas https://ClinicalTrials.gov/show/NCT01793233 Active, not recruiting Children’s Oncology Group 2020-12-31
NCT01366170 Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT01366170 Completed Children’s Oncology Group 2016-05-31
NCT03942263 A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation https://ClinicalTrials.gov/show/NCT03942263 Recruiting Takeda 2023-05-10
NCT03603847 Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma https://ClinicalTrials.gov/show/NCT03603847 Recruiting The Lymphoma Academic Research Organisation 2023-07-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT01793168 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford https://ClinicalTrials.gov/show/NCT01793168 Recruiting Sanford Health 2100-12-31
NCT04220970 Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry https://ClinicalTrials.gov/show/NCT04220970 Recruiting The Lymphoma Academic Research Organisation 2032-06-07
NCT03766516 Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL https://ClinicalTrials.gov/show/NCT03766516 Recruiting Samsung Medical Center 2020-06-30